Amendment to the Specification:

Applicant respectfully requests that the Abstract on page 77 be deleted in its entirety and replaced with the following:

- -

ABSTRACT

3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS

The present invention concerns the compounds of formula

$$R^{1}$$
 N^{6}
 N^{1}
 N^{2}
 N^{1}
 N^{2}
 N^{1}
 N^{2}
 N^{3}
 N^{2}
 N^{3}
 N^{2}
 N^{3}
 N^{2}
 N^{3}
 N^{2}
 N^{3}
 N^{3

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m, n, R¹, R², R³, R⁴ and R⁵ are as defined herein, the use of such compounds as inhibitors of cyclin-dependent serine/threonine kinases (Cdks), as well as kinases and phosphatases involved in cell cycle regulation such as the tyrosine kinases Wee1, Mik1 and Myt1 or the tyrosine dephosphatases such as Cdc25 and Pyp3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating cell proliferative disorders such as atherosclerosis, restenosis and cancer. - -